JP7472122B2 - コルチコステロイドを投与する方法 - Google Patents

コルチコステロイドを投与する方法 Download PDF

Info

Publication number
JP7472122B2
JP7472122B2 JP2021525303A JP2021525303A JP7472122B2 JP 7472122 B2 JP7472122 B2 JP 7472122B2 JP 2021525303 A JP2021525303 A JP 2021525303A JP 2021525303 A JP2021525303 A JP 2021525303A JP 7472122 B2 JP7472122 B2 JP 7472122B2
Authority
JP
Japan
Prior art keywords
dose
corticosteroid
urinary
patient
hsd1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021525303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507103A (ja
JPWO2020106337A5 (enExample
Inventor
カッツ，デイビッド，エー．
Original Assignee
スパロー ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スパロー ファーマシューティカルズ，インコーポレーテッド filed Critical スパロー ファーマシューティカルズ，インコーポレーテッド
Publication of JP2022507103A publication Critical patent/JP2022507103A/ja
Publication of JPWO2020106337A5 publication Critical patent/JPWO2020106337A5/ja
Priority to JP2024063590A priority Critical patent/JP2024098991A/ja
Application granted granted Critical
Publication of JP7472122B2 publication Critical patent/JP7472122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021525303A 2018-11-20 2019-08-14 コルチコステロイドを投与する方法 Active JP7472122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024063590A JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769932P 2018-11-20 2018-11-20
US62/769,932 2018-11-20
PCT/US2019/046449 WO2020106337A1 (en) 2018-11-20 2019-08-14 Methods for administering corticosteroids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063590A Division JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Publications (3)

Publication Number Publication Date
JP2022507103A JP2022507103A (ja) 2022-01-18
JPWO2020106337A5 JPWO2020106337A5 (enExample) 2022-08-23
JP7472122B2 true JP7472122B2 (ja) 2024-04-22

Family

ID=70774135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525303A Active JP7472122B2 (ja) 2018-11-20 2019-08-14 コルチコステロイドを投与する方法
JP2024063590A Pending JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024063590A Pending JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Country Status (10)

Country Link
US (2) US12220412B2 (enExample)
EP (1) EP3883578A4 (enExample)
JP (2) JP7472122B2 (enExample)
CN (1) CN113329754A (enExample)
AU (2) AU2019384074B2 (enExample)
BR (1) BR112021009653A2 (enExample)
CA (1) CA3120339A1 (enExample)
IL (2) IL283069B2 (enExample)
MX (2) MX2021005801A (enExample)
WO (1) WO2020106337A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス，インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
CA3128954A1 (en) * 2019-02-08 2020-08-13 Sanofi Biotechnological optimization of microorganisms for the 1,2-dehydrogenation of steroids
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
CA3250533A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR TREATING EXCESS GLUCOCORTICOIDS
WO2025072521A1 (en) * 2023-09-27 2025-04-03 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid-mediated diseases
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528308A (ja) 2001-03-23 2004-09-16 ザ ユニバーシティ オブ エディンバラ 脂質プロフィールのモジュレーション
US20050277647A1 (en) 2004-04-29 2005-12-15 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2010121814A1 (en) 2009-04-22 2010-10-28 Ontochem Gmbh Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist
WO2012033070A1 (ja) 2010-09-07 2012-03-15 アステラス製薬株式会社 疼痛治療剤
US20130338169A1 (en) 2004-04-29 2013-12-19 Abbvie Inc. Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
GB0101447D0 (en) 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
US20030148987A1 (en) 2001-12-21 2003-08-07 Morris David J. Selective 11beta-HSD inhibitors and methods of use thereof
JP4368683B2 (ja) 2002-02-01 2009-11-18 メルク エンド カムパニー インコーポレーテッド 糖尿病、肥満症および脂質代謝異常の治療に有用な１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
PL375256A1 (en) 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
JP2006522747A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 縮合１，２，４−トリアゾールの薬学的使用
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
US8026264B2 (en) 2003-05-29 2011-09-27 Merck Sharp And Dohme Corp. Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1
JP2007509959A (ja) 2003-10-28 2007-04-19 アムゲン インコーポレイティッド トリアゾール化合物およびそれに関連する使用法
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
EA200600990A1 (ru) 2003-12-19 2006-10-27 Пфайзер Инк. Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
US7507832B2 (en) 2003-12-22 2009-03-24 Eli Lilly And Company Triazole PPAR modulators
EP1732904B1 (en) 2004-03-29 2014-03-19 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
CA2580409C (en) 2004-09-16 2013-08-13 Astellas Pharma Inc. Triazole derivative or salt thereof
JP2008518903A (ja) 2004-11-02 2008-06-05 ファイザー・インク 置換および非置換アダマンチルアミドの新規化合物
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
WO2006080533A1 (ja) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
ES2334518T3 (es) 2005-06-16 2010-03-11 Pfizer, Inc. Derivados de n-(piridin-2-il)-sulfonamida.
CN101198605A (zh) 2005-06-16 2008-06-11 辉瑞大药厂 N-(吡啶-2-基)-磺酰胺衍生物
JPWO2007007688A1 (ja) 2005-07-08 2009-01-29 持田製薬株式会社 ３，５−ジアミノ−１，２，４−トリアゾール誘導体
US7615569B2 (en) 2005-08-16 2009-11-10 Icagen, Inc. Inhibitors of ion channels
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
BRPI0708782A2 (pt) 2006-03-16 2011-06-14 Astellas Pharma Inc derivado de triazol ou um sal deste
US20070224298A1 (en) 2006-03-23 2007-09-27 Talbott Shawn M Inhibiting 11(beta)-hsd1 with citrus flavonoids
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
MX2011000179A (es) * 2008-07-03 2011-04-05 Astellas Pharma Inc Derivado de triazol o su sal.
US8871208B2 (en) 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
CA2866220A1 (en) * 2012-03-13 2013-09-19 Abbvie Inc. Method for selecting or identifying a subject for v1b antagonist therapy
CN113018300B (zh) * 2014-07-09 2025-11-25 爱普制药有限责任公司 用于治疗神经病症的方法
EA036757B1 (ru) 2015-04-07 2020-12-17 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
US10648506B2 (en) 2016-07-07 2020-05-12 Raul Mendoza Walking rig creeper interface
WO2018117063A1 (ja) 2016-12-20 2018-06-28 アステラス製薬株式会社 焦燥性興奮治療剤
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
WO2023225507A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
CA3250533A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR TREATING EXCESS GLUCOCORTICOIDS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528308A (ja) 2001-03-23 2004-09-16 ザ ユニバーシティ オブ エディンバラ 脂質プロフィールのモジュレーション
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
US20050277647A1 (en) 2004-04-29 2005-12-15 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20130338169A1 (en) 2004-04-29 2013-12-19 Abbvie Inc. Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2010121814A1 (en) 2009-04-22 2010-10-28 Ontochem Gmbh Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist
WO2012033070A1 (ja) 2010-09-07 2012-03-15 アステラス製薬株式会社 疼痛治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
British Journal of Pharmacology，2018年，175，pp.3784-3796

Also Published As

Publication number Publication date
IL283069B1 (en) 2025-05-01
AU2025203033A1 (en) 2025-05-22
CN113329754A (zh) 2021-08-31
US20210393622A1 (en) 2021-12-23
CA3120339A1 (en) 2020-05-28
BR112021009653A2 (pt) 2021-08-17
WO2020106337A1 (en) 2020-05-28
US20250205227A1 (en) 2025-06-26
JP2022507103A (ja) 2022-01-18
MX2021005801A (es) 2021-08-05
EP3883578A1 (en) 2021-09-29
AU2019384074B2 (en) 2025-04-10
US12220412B2 (en) 2025-02-11
MX2025002836A (es) 2025-04-02
IL283069B2 (en) 2025-09-01
IL319327A (en) 2025-05-01
JP2024098991A (ja) 2024-07-24
AU2019384074A1 (en) 2021-06-03
EP3883578A4 (en) 2022-07-27
IL283069A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
JP7472122B2 (ja) コルチコステロイドを投与する方法
US20220249515A1 (en) Ganaxolone for use in treating genetic epileptic disorders
US10940156B2 (en) Neuroactive steroids, compositions, and uses thereof
TWI784261B (zh) 神經活性類固醇，其組合物及其用途
CN112533611A (zh) 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
TW202341995A (zh) 用於治療cns相關病症之神經活性類固醇
KR20240006026A (ko) 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
KR20230158033A (ko) 주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
KR20200062241A (ko) 시포니모드의 투여 요법
JP2019507786A (ja) 慢性閉塞性肺疾患の急性増悪の治療のための投与レジメン
NO332723B1 (no) Anvendelse av glukokortikoidreseptorantagonist for fremstilling av medikamenter til inhibering av kognitiv svekkelse hos voksne med Downs syndrom
JP2019522033A (ja) アルツハイマー病治療に関連するアミロイド関連画像異常の治療または予防方法
JP2019507785A (ja) 炎症状態の急性増悪の治療のための投与レジメン
MXPA04007309A (es) Tratamiento de artritis reumatoide.
EP4243782B1 (en) Tablet for use in treating huntington's disease and method of making the same
CN110831590A (zh) 含有培马贝特的医药
US12419881B1 (en) Methods of using radiprodil in the treatment of disorders
JP2024501259A (ja) 静脈内バクロフェンの投与方法
HK40101454A (en) Tablet for use in treating huntington's disease and method of making the same
HK40101454B (en) Tablet for use in treating huntington's disease and method of making the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240410

R150 Certificate of patent or registration of utility model

Ref document number: 7472122

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150